First Report of Use of a New Filter Approved for COVID 19 Patients in Extracorporeal Circulation.
Juan Bustamante Munguira, Prof., Eduardo Velasco, Cristina Sanchez, Barbara Segura, Lucia Pañeda, Mireia Fernandez, Jose Ramon Echevarria, Virginia Serrano
Hospital Clinico Universitario de Valladolid, Valladolid, Spain
OBJECTIVE: Extracorporeal circulation (ECC) provoke a pro inflammatory response. Currently its importance increased associated a COVID 19 patients for their pro coagulant state. Recently, the use of filter to mitigate this response gain protagonim with the objective to reduce pro-inflammatory mediators. Our aim is to share our experience with the use of a new filter approved, FDA authorization (EUA200165), for the treatment of COVID 19 but not design for ECC.
METHODS: In order to prepare for cardiac surgery COVID-19 patients, we tested the new filter on a scheduled basis in a patient with coronary artery disease and a history of HIV. The patient was informed and CABG x 3 was performed. It was not easy to find a way to connect the filter to the ECC circuit. We needed to use a Kit.Emoconc.Diaf Eurosets (Medolla (MO) Italy).
RESULTS: The filter worked well, and we no observed any problems with its use. A marked reduction the principal inflammatory parameters (IL 6.8, PCR, procalcitonin and ferritin) was observed. The viral load disappears during one week. The evolution of the patient was nice and was discharge at 5 days.
CONCLUSIONS: This filter in cardiac surgery may be useful. The evolution of the SARS-CoV-2 pandemic worldwide is at different stages depending on the country. The possibility of new cases in the fall makes us have to redesign protocols in order to minimize their appearance and improve their treatment. The dissemination of information in such changing circumstances is essential for a better treatment of patients.
Back to 2020 Program